OQROGet OQRO Pro
Insider trade

Dexcom (DXCM)Director sold ~$15K

Mark G Foletta, Director at Dexcom, sold ~$15K of Dexcom shares.

~$15K
Approx. value · 199 sh @ $74.82
53K
Holds after · shares reported
Traded
Jun 15, 2026
Filed
Jun 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
  2. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
  3. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  4. Apr 29, 2026CongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000
  5. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  6. May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
  7. May 12, 2026InsiderDirector sold ~$61K of DXCM shares in the open market
  8. May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
  9. May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  10. May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  11. May 27, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Softwar…
  12. Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market
  13. Jun 4, 2026InsiderOfficer sold ~$364K of DXCM shares in the open market
  14. Jun 8, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System
  15. Jun 12, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  16. Jun 15, 2026 · this disclosureInsiderDirector sold ~$15K of DXCM shares in the open market

What came next

  1. Jun 15, 2026Insider · 2 peopleInsiders: 2 sales (~$410K)
  2. Jul 6, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  3. Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
  4. Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
  5. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  6. Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
  7. Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market
  8. Aug 11, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  9. Aug 12, 2026InsiderDirector sold ~$89K of DXCM shares in the open market
  10. Aug 14, 2026InsiderOfficer sold ~$156K of DXCM shares in the open market
  11. Aug 20, 2026Insider · 1 personInsiders: 3 sales (~$2.4M)
  12. Aug 27, 2026InsiderOfficer sold ~$227K of DXCM shares in the open market
  13. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.”
  14. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.”
  15. Sep 10, 2026InsiderOfficer sold ~$303K of DXCM shares in the open market
  16. Sep 14, 2026InsiderDirector sold ~$130K of DXCM shares in the open market
  17. Sep 15, 2026Insider · 2 peopleInsiders: 2 sales (~$692K)
  18. Sep 28, 2026InsiderOfficer sold ~$221K of DXCM shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Mark G Foletta, Director

The full history of Mark G Foletta, Director is on the profile page.

How this filing works

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data